Journals / The Journal of Pediatric Research / 2018 / Cilt: 5 - Sayı: 1

Tyrosinemia Type I and Reversible Neurogenic Crisis After a One-Month Interruption of Nitisinone

Pages
57–59
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

With the re-introduction of NTBC, the patient gradually reacquired normal neurological functions, normal blood pressure and recovered completely

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hereditary tyrosinemia Type I (HTI) is an autosomal recessive disorder due to a deficiency of the enzyme fumarylacetoacetate hydrolase.
📊
Key Findings & Data:An effective treatment has been available with 2-[2-nitro-4-trifluoromethylbenzoyl]-1,3-cyclohexanedione (NTBC) since 1992.
💡
Conclusion & Impact:With the re-introduction of NTBC, the patient gradually reacquired normal neurological functions, normal blood pressure and recovered completely
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Hereditary tyrosinemia Type I (HTI) is an autosomal recessive disorder due to a deficiency of the enzyme fumarylacetoacetate hydrolase. The liver is the primary organ that is affected and comorbidities with renal and neurologic systems and hepatocellular carcinoma can be seen as a long-term complication. An effective treatment has been available with 2-[2-nitro-4-trifluoromethylbenzoyl]-1,3-cyclohexanedione (NTBC) since 1992. Neurogenic crises do not take place in HTI patients who are treated with NTBC. Here, we report on a seven-year-old boy who underwent a severe neurological crisis including anorexia, vomiting, weakness, hyponatremia, paresthesia and paralysis of the extremities, seizure and arterial hypertension after an interruption of NTBC treatment. With the re-introduction of NTBC, the patient gradually reacquired normal neurological functions, normal blood pressure and recovered completely

🔖

Cite This Article

YAZICI, H., CANDA, E., ER, E., KILINÇ, M. A., UÇAR, S. K., KARAPINAR, B., ÇOKER, M. (2018). Tyrosinemia Type I and Reversible Neurogenic Crisis After a One-Month Interruption of Nitisinone. The Journal of Pediatric Research, Cilt: 5 - Sayı: 1, 57–59. https://ajindex.com/articles/362782

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Chakrapani A, Gissen P, McKierrnan P. Disorders of tyrosine metabolism. In: Saudubray JM, van den Berghe G, Walter JH (eds). Inborn metabolic diseases, diagnosis and treatment, 6th ed. Heidelgerg, Springer 2016:265-76. van Spronsen FJ, Thomasse Y, Smit GP, et al. Hereditary tyrosinemia Type I: A new clinical classification with difference in prognosis on dietary treatment. Hepatology 1994;20:1187-91.
  2. Chinsky JM, Singh R, Ficicioglu C, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med 2017:19. Larochelle J, Alvarez F, Bussières JF, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec. Mol Genet Metab 2012;107:49-54.
  3. Schlump JU, Perot C, Ketteler K, et al. Severe neurological crisis in a patient with hereditary tyrosinaemia type I after interruption of NTBC treatment. J Inherit Metab Dis 2008;31(Suppl 2):223-5.
  4. Zeybek AC, Kiykim E, Soyucen E, et al. Hereditary tyrosinemia type 1 in Turkey: twenty year single center experience. Pediatr Int 2015;57:281-9.
  5. Onenli Mungan N, Yıldızdaş D, Kör D, et al. Tyrosinemia type 1 and irreversible neurologic crisis after one month discontinuation of nitisone. Metab Brain Dis 2016;31:11813.